<DOC>
	<DOCNO>NCT00991757</DOCNO>
	<brief_summary>The purpose open-label extension study demonstrate RWJ-333369 safe long-term add-on treatment partial onset seizure .</brief_summary>
	<brief_title>An Open-Label Extension Study Evaluate Safety Tolerability RWJ 333369 Adjunctive Therapy Patients 16 Years Older With Partial Onset Seizures .</brief_title>
	<detailed_description>333369EPY3004 open-label extension study follow double-blind study 333369EPY3001 333369EPY3002 ( NCT00425282 NCT00433667 , respectively ) . In open label study 333369EPY3004 , physician patient know name assign study medication . In double blind study 333369EPY3001 333369EPY3002 , neither physician patient know name assign study medication . Patients complete double-blind treatment phase study 333369EPY3001 333369EPY3002 eligible enter open-label extension study 333369EPY3004 patient transition blind period open-label period carisbamate ( also refer RWJ-333369 ) . There blinded transition patient take blind study medication ; , patient take unblinded , open-label study medication . No patient receive placebo open-label extension . Safety assessment include monitoring frequency , severity , time adverse event , clinical laboratory test result , 12-lead electrocardiogram ( ECG ) recording , vital sign measurement , physical neurologic examination , Physician Withdrawal Checklist symptom withdrawal patient taper and/or discontinue study drug , pregnancy test females childbearing potential . Seizure count obtain every visit . A Quality Life Epilepsy questionnaire administer study . There statistical test hypothesis study . Detailed Description update,5 Oct 2009 . The Sponsor conjunction DSMB agree amend protocol withdraw patient develop sign drug hypersensitivity reaction . Open-label treatment carisbamate 400 mg/day ( maximum 1200mg/day ) give 2 equally divided dos BID 1 year ; study drug swallow whole chewed , divide , crush , dissolve .</detailed_description>
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsies , Partial</mesh_term>
	<mesh_term>Epilepsy , Complex Partial</mesh_term>
	<criteria>In order enter open label extension , patient must complete either Study 333369EPY3001 Study 333369EPY3002 . Generalized epilepsy Currently experience seizure count accurately Unstable medical disease , recent heart attack uncontrolled diabetes Major psychiatric illness Recent drug alcohol abuse Unable swallow pill</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>RWJ-333369</keyword>
	<keyword>Anticonvulsants</keyword>
	<keyword>Antiepileptic drug</keyword>
	<keyword>Epilepsy , Focal</keyword>
	<keyword>Seizure Disorder</keyword>
</DOC>